Literature DB >> 3364953

Pharmacokinetics of carumonam after single and multiple 1- and 2-g dosage regimens.

D Bérubé1, F Vallée, A C Panneton, M G Bergeron, M LeBel.   

Abstract

The pharmacokinetics of carumonam after single and multiple intravenous administration of 1- and 2-g dosage regimens were studied in 12 young male volunteers. Plasma and urine samples were collected in serial order for 24 h and assayed by high-pressure liquid chromatography. The mean elimination half-life of carumonam was not significantly affected by either dosage regimen or single dose versus steady state, ranging from 1.3 to 1.5 h. Mean concentrations at the end of the interval were not influenced by a multiple-dose administration. The normalized volume of distribution was independent of the dose, with values ranging from 0.16 to 0.19 liters/kg. After multiple administration, carumonam was cleared from the body more rapidly: from 96.2 to 121.7 ml/min after 1 g every 8 h, and from 102.1 to 122.3 ml/min after 2 g every 8 h (P less than 0.05). After 24 h, 75.0 to 80.7% of the dose was excreted unchanged in the urine. The protein binding of carumonam to human plasma remained stable at 28%. Carumonam was well tolerated by the volunteers.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3364953      PMCID: PMC172175          DOI: 10.1128/AAC.32.3.354

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Determination of the monocyclic beta-lactam antibiotic carumonam in plasma and urine by ion-pair and ion-suppression reversed-phase high-performance liquid chromatography.

Authors:  H J Egger; G Fischer
Journal:  J Chromatogr       Date:  1987-09-25

Review 2.  Clearance approaches in pharmacology.

Authors:  G R Wilkinson
Journal:  Pharmacol Rev       Date:  1987-03       Impact factor: 25.468

3.  Noncompartmental determination of the steady-state volume of distribution for any mode of administration.

Authors:  D Perrier; M Mayersohn
Journal:  J Pharm Sci       Date:  1982-03       Impact factor: 3.534

4.  The in-vitro activity and beta-lactamase stability of carumonam.

Authors:  H C Neu; N X Chin; P Labthavikul
Journal:  J Antimicrob Chemother       Date:  1986-07       Impact factor: 5.790

5.  Renal excretion of cephapirin and cephaloridine: evidence for saturable tubular reabsorption.

Authors:  A Arvidsson; O Borgå; G Alván
Journal:  Clin Pharmacol Ther       Date:  1979-06       Impact factor: 6.875

6.  Pharmacokinetics and dose recommendations of carumonam in renal failure.

Authors:  P Koeppe; D Höffler; K Strobel
Journal:  Arzneimittelforschung       Date:  1987-01

7.  In vitro and in vivo antibacterial activities of carumonam (AMA-1080), a new N-sulfonated monocyclic beta-lactam antibiotic.

Authors:  A Imada; M Kondo; K Okonogi; K Yukishige; M Kuno
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

8.  Antibiotics in the second half of the 1980s. Areas of future development and the effect of new agents on aminoglycoside use.

Authors:  H C Neu
Journal:  Am J Med       Date:  1986-06-30       Impact factor: 4.965

9.  Pharmacokinetics of carumonam in patients with renal insufficiency.

Authors:  F Horber; H J Egger; E Weidekamm; U C Dubach; F J Frey; P J Probst; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

10.  Pharmacokinetics and tissue penetration of carumonam, a new synthetic monobactam.

Authors:  C A McNulty; G M Garden; J Ashby; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1985-09       Impact factor: 5.191

View more
  1 in total

1.  Pharmacokinetics of carumonam (AMA-1080) in patients with impaired renal function and in those undergoing hemodialysis.

Authors:  K Konishi; H Suzuki; T Saruta; N Deguchi; T Fugono
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.